Abstract
Cardiovascular diseases are the leading causes of morbidity and mortality in many industrialized societies. Atherosclerosis is the major risk factor for the development of cardiovascular disease based on arterial endothelial dysfunction caused by the impairment of endothelial-dependent dilation. Atherosclerosis is a complex vascular disease resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of a non-redundant role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) may be directly involved in the development of multiple atherogenic mechanisms including advanced oxidative stress, abnormalities in glucose and fat metabolism, and altered energy homeostasis. Recent findings showed that the heteroplasmy level of some somatic mtDNA is associated with coronary atherosclerosis. Although this field should further widely elaborated, heteroplasmic mtDNA mutations could represent a new promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologic conditions. In this review, we critically consider the contribution of mitochondria-related factors to the pathogenesis of the arterial vascular pathology.
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, mitochondrial dysfunction, oxidative stress, cell functions.
Current Pharmaceutical Design
Title:Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Volume: 19 Issue: 33
Author(s): Igor A. Sobenin, Dimitry A. Chistiakov, Yuri V. Bobryshev, Anton Y. Postnov and Alexander N. Orekhov
Affiliation:
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, mitochondrial dysfunction, oxidative stress, cell functions.
Abstract: Cardiovascular diseases are the leading causes of morbidity and mortality in many industrialized societies. Atherosclerosis is the major risk factor for the development of cardiovascular disease based on arterial endothelial dysfunction caused by the impairment of endothelial-dependent dilation. Atherosclerosis is a complex vascular disease resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of a non-redundant role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) may be directly involved in the development of multiple atherogenic mechanisms including advanced oxidative stress, abnormalities in glucose and fat metabolism, and altered energy homeostasis. Recent findings showed that the heteroplasmy level of some somatic mtDNA is associated with coronary atherosclerosis. Although this field should further widely elaborated, heteroplasmic mtDNA mutations could represent a new promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologic conditions. In this review, we critically consider the contribution of mitochondria-related factors to the pathogenesis of the arterial vascular pathology.
Export Options
About this article
Cite this article as:
Sobenin A. Igor, Chistiakov A. Dimitry, Bobryshev V. Yuri, Postnov Y. Anton and Orekhov N. Alexander, Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications, Current Pharmaceutical Design 2013; 19(33) . https://dx.doi.org/10.2174/1381612811319330013
DOI https://dx.doi.org/10.2174/1381612811319330013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mice with Liver Composed of Human Hepatocytes as an Animal Model for Drug Testing
Current Drug Discovery Technologies Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research Diabetic Cognitive Dysfunction: From Bench to Clinic
Current Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Pre-eclampsia Versus Cardiovascular Disease Versus CRP
Current Hypertension Reviews Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Inhibitory Effect of Copper on Cystathionine β-Synthase Activity: Protective Effect of an Analog of the Human Albumin N-Terminus
Protein & Peptide Letters Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology